Linden Thomas Advisory Services, LLC Halozyme Therapeutics, Inc. Transaction History
Linden Thomas Advisory Services, LLC
- $647 Billion
- Q2 2024
A detailed history of Linden Thomas Advisory Services, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Linden Thomas Advisory Services, LLC holds 35,328 shares of HALO stock, worth $2.09 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
35,328
Previous 42,497
16.87%
Holding current value
$2.09 Million
Previous $1.73 Billion
7.0%
% of portfolio
0.29%
Previous 0.28%
Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
489Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$763 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$344 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$239 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$220 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.25B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...